Irinotecan
Small molecule targets TOP1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ONIVYDE | — | 2024-02-13 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | CAMPTOSAR | — | 1998-10-22 – 2004-06-24 | fda.gov ↗ |
| Approved | US (FDA) | CAMPTOSAR | — | 1996-06-14 | fda.gov ↗ |
Trials 1,223 · started per year
Press releases naming this drug 55 releases
Evidence & citations 50 cited values
Every value below carries the sentence it was read from. 1,844 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | irinotecan | “Patients with colorectal adenocarcinoma (CRC) received a single administration of 0.6 milligrams (mg) / kilograms (kg) of BI 905711 intravenously on Day 3 of each 14-day cycle....” NCT05087992 ↗1695“Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to...” NCT05959356 ↗ “Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2...” NCT00778830 ↗ “Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations: * Carboplatin; * Irinotecan; * Etoposide; *...” NCT03632135 ↗ “Patients were randomly assigned (1:1; block size of three), without stratification, to receive FOLFIRI (irinotecan 180 mg/m2, calcium folinate 400 mg/m2 or levofolinate 200...” PMID 36739879 ↗ Feb 2023 “Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT),...” NCT06841159 ↗ “It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400...” NCT01124630 ↗ “mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes,...” NCT03099265 ↗ “The FOLFOXIRI chemotherapy regimen (5-fluorouracil, leucovorin, oxaliplatin, irinotecan) will be administered according to the study protocol as part of total neoadjuvant...” NCT07277842 ↗ “Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous...” NCT01446458 ↗ “Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV...” NCT04084496 ↗ |
| Known as | Aili | “Irinotecan monotherapy (trade name: Aili; batches 180103AG” NCT02030678 ↗ |
| Known as | BAX2398 | “BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate” NCT02697058 ↗ |
| Known as | Campto | “A Multicenter Randomized Phase II Study Evaluating The Activity And Tolerability Of Three Different Combinations Of Docetaxel (Taxotere) And Irinotecan (Campto) As Second Line...” NCT00139711 ↗12“A Phase 2 Study of the Efficacy and Safety of Irinotecan (Campto®) in Combination With Capecitabine (Xeloda®) as First-Line Chemotherapy in Asian Subjects With Inoperable...” NCT00635323 ↗ “Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.” NCT01526135 ↗ “Irinotecan (Campto®): 180 mg/m² on D1 by IV infusion in 250 mL of 0.9% saline over 90 minutes.” NCT00467142 ↗ “Irinotecan Hydrochloride Injection（CAMPTO®） pharmacokinetics comparative study” NCT04088604 ↗ “180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes” NCT00561470 ↗ “irinotecan (Campto®) 180 mg/m² on D1, IV infusion over 90 minutes” NCT02967289 ↗ “Nexavar (Sorafenib) and irinotecan (Campto)” NCT00989469 ↗ “Irinotecan = Camptosar, Campto, or CPT-11” NCT00996346 ↗ |
| Known as | Camptosar | “The standard and approved treatment for patients with metastatic colorectal cancer is repeated cycles of chemotherapy consisting of a combination of irinotecan (also known as...” NCT00037180 ↗20“irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous...” NCT05004350 ↗ “PURPOSE: To determine the activity, toxicity, and pharmacokinetics of irinotecan (CPT-11, Camptosar; Pharmacia & Upjohn, Kalamazoo, MI) in the treatment of adults with...” PMID 10334539 ↗ May 1999 “Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas,...” NCT00381797 ↗ “A Phase I Study of ZD1839 (Iressa) in Combination With Irinotecan (Camptosar or CPT-11) and Vincristine in Pediatric Patients With Refractory Solid Tumors” NCT00186979 ↗ “A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract” NCT00020761 ↗ “Folinic acid at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin, and concurrently with irinotecan (Camptosar).” NCT03374852 ↗ “Phase II Study for the Evaluation of CPT-11 (Irinotecan, Camptosar) in Patients With Metastatic or Recurrent Breast Cancer” NCT00004182 ↗ “irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.” NCT06047379 ↗ “180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes” NCT00561470 ↗ “Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1” NCT01523431 ↗ |
| Known as | Camptothecin-11 | “irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous...” NCT05004350 ↗ |
| Known as | CPT-11 | “PURPOSE: The aims of this trial were to assess the safety and efficacy of two different dosing schedules of irinotecan (CPT-11) in recurrent glioma patients, to assess...” PMID 19066728 ↗ Dec 200876“The standard and approved treatment for patients with metastatic colorectal cancer is repeated cycles of chemotherapy consisting of a combination of irinotecan (also known as...” NCT00037180 ↗ “irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous...” NCT05004350 ↗ “We hypothesized that germline polymorphisms within genes related to drug target (thymidylate synthase) or metabolizing enzymes (UDP-glucuronosyltransferase, UGT) would impact...” PMID 15709193 ↗ Feb 2005 “This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects...” NCT00165464 ↗ “A Phase I/II Study to Evaluate Safety and Efficacy in Patients Who Have Resectable Esophageal Cancer and Are Treated With Neoadjuvant Cisplatin, Irinotecan (CPT-11) ZD1839...” NCT00290719 ↗ “PURPOSE: To determine the activity, toxicity, and pharmacokinetics of irinotecan (CPT-11, Camptosar; Pharmacia & Upjohn, Kalamazoo, MI) in the treatment of adults with...” PMID 10334539 ↗ May 1999 “We had previously demonstrated that low dose irinotecan (CPT-11) leads to increased accumulation of cells in S-phase and shows a therapeutic synergy with S-phase specific...” PMID 18594219 ↗ Aug 2008 “Significant activity (radiographic response rates of approximately 60%) has recently been demonstrated in phase II studies in patients with relapsed GBM from the combined use...” NCT00817284 ↗ “Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for...” NCT00003835 ↗ “nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan free base, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug...” NCT03328884 ↗ |
| Known as | CPT-11:Irinotecan | “CPT-11:Irinotecan” NCT01424709 ↗ |
| Known as | HE072 | “This study (NCT04728035) aimed to explore the safety and efficacy of liposomal irinotecan (HE072) in patients with metastatic triple-negative breast cancer (mTNBC).” PMID 39746964 ↗ Jan 2025 |
| Known as | HR070803 | “This randomized, double-blind, parallel-controlled, multicenter phase 3 study (NCT05074589) assessed the efficacy and safety of liposomal irinotecan HR070803 combined with...” PMID 39300077 ↗ Sep 20241“Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study.” PMID 39037543 ↗ Jul 2024 |
| Known as | IRI | “the aim of the present NEXIRI-2/PRODIGE 27 trial was to assess the 2-month non-progression rate for sorafenib (NEX) plus irinotecan (IRI), that is, NEXIRI, treatment.” PMID 32737004 ↗ May 20209“FOLFIRI (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and irinotecan \[IRI\]) was supplied as solutions for intravenous administration.” NCT00959647 ↗ “FOLFIRI is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and irinotecan (IRI) which acts as systemic cytotoxic agent.” NCT03250832 ↗ “Patients are planned to receive the SIRIOX regimen including Irinotecan (IRI, 180mg/m2; day 1,day 15) of every cycle” NCT03403101 ↗ “Leucovorin calcium (folinic acid)(FOL) + fluorouracil \[F\] + irinotecan \[IRI\]” NCT00551213 ↗ “bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide” PMID 29121274 ↗ Jun 2018 “Irinotecan (IRI) - Starting dose 180 mg/m2” NCT02726334 ↗ “Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1;” NCT04160416 ↗ “Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1” NCT04508452 ↗ “irinotecan (Iri) at progression” PMID 34507244 ↗ Sep 2021 |
| Known as | Irinotecan (campto, CPT-11) | “Irinotecan (campto, CPT-11)” NCT00166881 ↗ |
| Known as | Irinotecan (Camptosar) | “Irinotecan (Camptosar)” NCT02178709 ↗3“Irinotecan (Camptosar)” NCT00856830 ↗ “Irinotecan, Camptosar®” NCT00003950 ↗ “Irinotecan (Camptosar)” NCT02568046 ↗ |
| Known as | Irinotecan (CPT-11) | “Irinotecan (CPT-11)” NCT02624726 ↗ |
| Known as | Irinotecan (irinotecan HCl, CPT-11 or Campto, Aventis) | “Irinotecan (irinotecan HCl, CPT-11 or Campto®, Aventis)” NCT00153998 ↗ |
| Known as | Irinotecan - Camptosar - CPT11 | “Irinotecan - Camptosar - CPT11” NCT00616005 ↗1“Irinotecan-Camptosar-CPT 11” NCT00612638 ↗ |
| Known as | Irinotecan Cell pharm | “Irinotecan (Irinotecan Cell pharm®)” NCT02085148 ↗ |
| Known as | Irinotecan HCl | “A Phase I Study to Evaluate Orally Administered Irinotecan HCL (CPT-11) Given as a Powder-Filled Capsule Formulation Daily for 14 Days Every Three Weeks in Patients With...” NCT00004051 ↗1“Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5” NCT01463982 ↗ |
| Known as | irinotecan hydrochloride | “OBJECTIVES:
I. To define the maximally tolerated dose of the combination of CPT-11 (irinotecan hydrochloride), oxaliplatin, and capecitabine in three different populations,...” NCT00074321 ↗185“To evaluate the objective response rate systemically and in the CNS to the combination of irinotecan hydrochloride and temozolomide among patients with breast cancer and...” NCT00617539 ↗ “This phase II trial studies how well giving irinotecan hydrochloride together with oxaliplatin and capecitabine works as first-line therapy in treating patients with metastatic...” NCT00433550 ↗ “Patients receive mFOLFIRINOX comprising oxaliplatin intravenously (IV) over 2 hours, levoleucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and...” NCT02047474 ↗ “Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA...” NCT07653685 ↗ “Patients received modified FOLFIRINOX treatment (85 mg/m2 of oxaliplatin, 180 mg/m2 of irinotecan hydrochloride, 400 mg/m2 of leucovorin calcium, and then 2400 mg/m2 of...” PMID 27275632 ↗ Aug 2016 “This phase II trial studies the side effects and how well irinotecan hydrochloride, oxaliplatin and cetuximab work in treating patients with unresectable or metastatic...” NCT00871169 ↗ “Patients receive irinotecan hydrochloride IV over 90 minutes and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2 (FOLFIRI).” NCT00537121 ↗ “Patients receive bevacizumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1.” NCT00628810 ↗ “To determine the dose-limiting toxicity and maximum tolerated dose of irinotecan hydrochloride according to the genotype status of Asian patients with solid tumors.” NCT00731276 ↗ “To evaluate the safety and efficacy of irinotecan (irinotecan hydrochloride) in breast cancer patients with brain metastases who progressed after radiation therapy.” NCT01939483 ↗ |
| Known as | Irinotecan hydrochloride hydrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02497157 ↗ |
| Known as | Irinotecan Hydrochloride Liposome Injection | “Irinotecan hydrochloride liposome Injection 80 mg/m² intravenously Days 1 q2wk” NCT06128837 ↗2“Irinotecan hydrochloride liposome injection: 70mg/m2, intravenous infusion” NCT06467786 ↗ “Drug: Irinotecan Hydrochloride Liposome Injection” NCT06499610 ↗ |
| Known as | Irinotecan hydrochloride trihydrate | “Irinotecan hydrochloride trihydrate is...” NCT04390399 ↗2“Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.” NCT03175016 ↗ “Drug: Irinotecan hydrochloride trihydrate” NCT00160875 ↗ |
| Known as | Irinotecan hydrochloride: CPT-11 | “Irinotecan hydrochloride: CPT-11” NCT00546130 ↗ |
| Known as | Irinotecan liposoma | “Drug: Irinotecan liposoma” NCT06782685 ↗ |
| Known as | Irinotecan Liposomal | “Drug: Irinotecan Liposomal” NCT06782685 ↗ |
| Known as | Irinotecan liposome injection | “Irinotecan liposome injection is irinotecan in the form of the sucrosofate salt, encapsulated in liposomes for i.v. infusion.” NCT04083235 ↗1“Drug: Irinotecan Liposome Injection” NCT04728035 ↗ |
| Known as | irinotecan liposome(II) | “Drug: irinotecan liposome(II) 70mg/m\^2, IV, D1, Q3W” NCT06820762 ↗ |
| Known as | Irinotecan Monohydrochloride Trihydrate | “Irinotecan Monohydrochloride Trihydrate” NCT02095132 ↗ |
| Known as | Irinotecan Sucrosofate | “irinotecan sucrosofate (liposomal irinotecan)” NCT06821997 ↗ |
| Known as | Irinotecan-CPT 11-Camptosar | “Irinotecan, (CPT 11),(Camptosar®)” NCT00931840 ↗1“Irinotecan-CPT 11-Camptosar” NCT00611728 ↗ |
| Known as | IRN | “This study evaluated the safety and dosing of the PARP1/2 inhibitor niraparib (NIR) with temozolomide (TMZ; arm 1) or irinotecan (IRN; arm 2) in patients with pretreated ES.” PMID 33289920 ↗ Dec 20201“irinotecan [IRN]” PMID 20530282 ↗ Jun 2010 |
| Known as | Liposomal Irinotecan | “Liposomal Irinotecan in Combination With Oxaliplatin and Bevacizumab Versus Liposomal Irinotecan in Combination With 5-FU/LV for the Second-line Treatment of Advanced Pancreatic Cancer” NCT06782685 ↗8“Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study.” PMID 39037543 ↗ Jul 2024 “RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.” PMID 38648575 ↗ Apr 2024 “Liposomal irinotecan is a form of the anticancer drug irinotecan that is contained inside very tiny, fat-like particles.” NCT06821997 ↗ “liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI)” NCT03861702 ↗ “Liposomal irinotecan is irinotecan encapsulated by liposomes, which has advantages in safety.” NCT06462105 ↗ “All patients receiving NALIRIFOX initiated liposomal irinotecan at the full starting dose.” PMID 42080361 ↗ May 2026 “Drug: Liposomal Irinotecan” NCT05255666 ↗ “Drug: Liposomal irinotecan” NCT05854498 ↗ |
| Known as | Liposomal irinotecan (II) | “Liposomal irinotecan (II) 60 mg/m² is administered by intravenous infusion over 90 minutes (±30 minutes), or according to institutional clinical practice, on Day 1 every 2 weeks (Q2W).” NCT07797816 ↗ |
| Known as | Liposomal Irinotecan Hydrochloride Injection (II) | “Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1” NCT06603376 ↗ |
| Known as | Liposome irinotecan | “Liposome irinotecan(50mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle” NCT07376499 ↗ |
| Known as | LY01610 | “A Multicenter, Randomized, Open-label, Parallel-design Phase 3 Study to Evaluate the Efficacy and Safety of LY01610 (Irinotecan Hydrochloride Liposome Injection) Versus...” NCT06128837 ↗ |
| Known as | MM-398 | “nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan free base, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug...” NCT03328884 ↗ |
| Known as | nal-IRI | “This prospective phase II, single arm, single site trial will evaluate the efficacy of the combination of liposomal irinotecan (nal-IRI), TAS102, and bevacizumab for the...” NCT05854498 ↗10“This is a Phase I and Early Efficacy Study of Convection Enhanced Delivery (CED) of irinotecan liposome injection (nal-IRI) Using Real Time Imaging with Gadolinium in Children...” NCT03086616 ↗ “We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in...” PMID 33284237 ↗ Feb 2021 “Liposomal Irinotecan (Nal-IRI) Plus 5-fluorouracil and Leucovorin (5-FU/LV) Plus Oxaliplatin (NALIRIFOX) as First-Line Chemotherapy for Patients With Advanced Small Intestine...” NCT07060014 ↗ “liposomal irinotecan (Nal-IRI) is a novel nanoliposome formulation of irinotecan that accumulates in tumor-associated macrophages improving the therapeutic index of irinotecan” PMID 33403007 ↗ Sep 2020 “Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique.” NCT05277766 ↗ “liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI)” NCT03861702 ↗ “Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w” NCT03044587 ↗ “substituting liposomal irinotecan (nal-IRI) for nonliposomal irinotecan” PMID 37753702 ↗ Sep 2023 “Liposomal Irinotecan (nal-IRI)” NCT05251038 ↗ “nal-IRI (ONIVYDE®)” NCT03703063 ↗ |
| Known as | nanoliposomal irinotecan | “Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk” NCT05385861 ↗ |
| Known as | NSC-616348 | “Randomized Phase III Trial of Cisplatin and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC)” NCT00045162 ↗1“A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors” NCT00708773 ↗ |
| Known as | Onivyde | “Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique.” NCT05277766 ↗9“Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid” NCT03528785 ↗ “liposomal irinotecan (Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV)” NCT02826486 ↗ “Irinotecan Liposomal Injection [Onivyde]” NCT03468335 ↗ “Irinotecan Liposomal Injection [Onivyde]” NCT04371224 ↗ |
| Known as | pegylated nanoliposomal irinotecan | “We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in...” PMID 33284237 ↗ Feb 2021 |
| Known as | PEP02 | “nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan free base, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug...” NCT03328884 ↗ |
| Known as | Topotesin | “Drug: Campto, Topotesin” NCT00209651 ↗1“Campto, Topotesin” NCT00316745 ↗ |
| Known as | U-101440E | “U-101440E” NCT00103259 ↗ |
| Known as | U101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07184827 ↗ |
| Action | Inhibit | “in vitro inhibition of topoisomerase I activity by irinotecan” NCT00002933 ↗ |
| Modality | Small molecule | “Irinotecan (CPT-11) is a promising camptothecin analogue” NCT00001495 ↗ |
| Route | Intravenous | “Patients receive cyclosporine IV over 6 hours and irinotecan IV over 90 minutes weekly for 4 weeks.” NCT00002759 ↗ |
| Target | TOP1 | “topoisomerase 1 (top1) inhibitor” NCT04514497 ↗ |